MAP2K7 and melanoma: This finding, the good results of BRAF–MEK combination treatment in malignant melanoma (12), and a recently published case reporting a response on single treatment with a BRAF inhibitor in a patient with LGSOC (10) formed the rationale to initiate BRAF–MEK inhibitor combination therapy for our patient.